Desferal
These highlights do not include all the information needed to use DESFERAL safely and effectively. See full prescribing information for DESFERAL. DESFERAL (deferoxamine mesylate) for injection, for intramuscular, intravenous, or subcutaneous use Initial U.S. Approval: 1968
Approved
Approval ID
a7174843-5965-49fc-b842-f7eff7b48bbc
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Aug 2, 2023
Manufacturers
FDA
Novartis Pharmaceuticals Corporation
DUNS: 002147023
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
deferoxamine mesylate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code0078-0467
Application NumberNDA016267
Product Classification
M
Marketing Category
C73594
G
Generic Name
deferoxamine mesylate
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Effective DateSeptember 9, 2022
FDA Product Classification
INGREDIENTS (1)
DEFEROXAMINE MESYLATEActive
Quantity: 500 mg in 1 1
Code: V9TKO7EO6K
Classification: ACTIB